NetraMark Holdings Inc. (AINMF)
OTCMKTS
· Delayed Price · Currency is USD
0.9390
+0.0690 (7.93%)
May 23, 2025, 4:00 PM EDT
NetraMark Holdings Revenue
NetraMark Holdings had revenue of 386.09K CAD in the quarter ending December 31, 2024, with 128,595.00% growth. This brings the company's revenue in the last twelve months to 841.91K, up 848.22% year-over-year. In the fiscal year ending September 30, 2024, NetraMark Holdings had annual revenue of 456.13K with 410.97% growth.
Revenue (ttm)
841.91K CAD
Revenue Growth
+848.22%
P/S Ratio
135.32
Revenue / Employee
n/a
Employees
n/a
Market Cap
79.18M USD
Revenue Chart
* This company reports financials in CAD.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Endo Inc. | 1.73B |
Veradigm | 588.02M |
Tian'an Technology Group | 1.78M |
Elite Pharmaceuticals | 70.00M |
Glass House Brands | 215.62M |
Northwest Biotherapeutics | 1.47M |
Silence Therapeutics | 27.70M |
BioStem Technologies | 332.45M |
NetraMark Holdings News
- 6 weeks ago - NETRAMARK TO HOST SHAREHOLDER CONFERENCE CALL TO DISCUSS BUSINESS MOMENTUM - PRNewsWire
- 7 weeks ago - NETRAMARK AND WORLDWIDE CLINICAL TRIALS ANNOUNCE AGREEMENT TO TRANSFORM CLINICAL TRIAL DESIGN WITH AI-POWERED PRECISION - PRNewsWire
- 8 months ago - Netramark to Present at the 2024 Cantech Letter Conference in Toronto, ON - Newsfile Corp
- 2 years ago - NETRAMARK, THE FIRST PUBLIC AI COMPANY TO LAUNCH CLINICAL TRIAL DE-RISKING TECHNOLOGY THAT INTEGRATES CHATGPT - PRNewsWire